

FOR IMMEDIATE RELEASE

Merlin Biotech CEO Dr. Randall Hyer Secures Two Major Awards at 2026 BioNJ Conference Competition

DOYLESTOWN, PA — May 15, 2026 — Merlin Biotech, Inc. is pleased to announce that its Chief Executive Officer, Dr. Randall N. Hyer, was the recipient of two top honors at the **2026 BioNJ BioPartnering Conference**. The event, a premier gathering of life sciences innovators and investors held at the Liberty Science Center, recognized the most impactful presentations from a field of nearly 85 competing companies.

Merlin Biotech achieved a significant double victory, winning in both categories for which it was nominated:

- **Most Memorable Presenter:** This individual award was presented to Dr. Randall N. Hyer for his standout performance and ability to engage the audience with Merlin Biotech's mission.
- **Best Company Presentation:** This award recognized **Merlin Biotech** for delivering the most comprehensive and effective organizational pitch of the conference.

"This year's BioPartnering Conference showcased the remarkable depth of innovation emerging across the life sciences ecosystem," said Debbie Hart, President and CEO of BioNJ. The recognition of Dr. Hyer and Merlin Biotech underscores the company's rising influence and the strength of its strategic vision in the biotechnology sector.

The conference featured extensive one-on-one partnering meetings and "Industry Connections" with global biopharma leaders, further solidifying Merlin Biotech's role in accelerating innovation to improve patient lives.

About Merlin Biotech, Inc.

Merlin Biotech is an innovative biotechnology company focused on the development of breakthrough cancer therapies. Led by CEO Randall N. Hyer, MD, PhD, MPH, the company is committed to high-impact science and collaborative growth within the global life sciences community.

Media Contact:

Investor Relations

info@merlinbiotech.com

(215) 589 6111

#